Abstract
IN 1976 the National Surgical Adjuvant Project for Breast and Bowel Cancers (NSABP) launched a multicenter randomized clinical trial to compare mastectomy with "lumpectomy," with and without radiation, in the treatment of breast cancer. Two years later, only a small fraction of the expected number of patients had been enlisted, and the trial was in jeopardy because of this low rate of accrual. What happened?In this issue of the Journal, Taylor and her colleagues present the results of a questionnaire study of why participating physicians entered so few of their eligible patients into the trial.1 They found a . . .

This publication has 15 references indexed in Scilit: